ES2123582T3 - Proteina con capacidad de formacion de huesos y procedimiento para su produccion. - Google Patents

Proteina con capacidad de formacion de huesos y procedimiento para su produccion.

Info

Publication number
ES2123582T3
ES2123582T3 ES93104650T ES93104650T ES2123582T3 ES 2123582 T3 ES2123582 T3 ES 2123582T3 ES 93104650 T ES93104650 T ES 93104650T ES 93104650 T ES93104650 T ES 93104650T ES 2123582 T3 ES2123582 T3 ES 2123582T3
Authority
ES
Spain
Prior art keywords
production
protein
procedure
bone formation
formation capacity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93104650T
Other languages
English (en)
Inventor
Egon Dr Amann
Yoko Otawara-Hamamoto
Reiko Kikuno
Sunao Takeshita
Kenichi Tezuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Aventis Pharmaceuticals Inc
Original Assignee
Nippon Hoechst Marion Roussel Ltd
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Hoechst Marion Roussel Ltd, Hoechst Marion Roussel Inc filed Critical Nippon Hoechst Marion Roussel Ltd
Application granted granted Critical
Publication of ES2123582T3 publication Critical patent/ES2123582T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION PONE A DISPOSICION LA SECUENCIA DE UNA NUEVA PROTEINA OSF-2 RELACIONADA CON LOS HUESOS QUE PUEDE SER OBTENIDA A PARTIR DE LOS TEJIDOS OSEOS DE LOS MAMIFEROS. LA INVENCION TIENE PREVISTO ADEMAS UN METODO DE PRODUCCION DE OSF-2 MEDIANTE TECNICAS RECOMBINANTES.
ES93104650T 1992-03-27 1993-03-22 Proteina con capacidad de formacion de huesos y procedimiento para su produccion. Expired - Lifetime ES2123582T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4071501A JPH05268982A (ja) 1992-03-27 1992-03-27 骨形成作用を有する新規な蛋白質およびその製造法

Publications (1)

Publication Number Publication Date
ES2123582T3 true ES2123582T3 (es) 1999-01-16

Family

ID=13462492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93104650T Expired - Lifetime ES2123582T3 (es) 1992-03-27 1993-03-22 Proteina con capacidad de formacion de huesos y procedimiento para su produccion.

Country Status (9)

Country Link
US (1) US5756664A (es)
EP (1) EP0562508B1 (es)
JP (1) JPH05268982A (es)
AT (1) ATE167232T1 (es)
CA (1) CA2092768A1 (es)
DE (1) DE69319012T2 (es)
DK (1) DK0562508T3 (es)
ES (1) ES2123582T3 (es)
GR (1) GR3027671T3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889159A (en) * 1993-10-29 1999-03-30 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to tumor marker TC1 and methods for use of same
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AU744087B2 (en) 1997-05-29 2002-02-14 Board Of Regents, The University Of Texas System OSF2/CBFA1 compositions and methods of use
EP1524524A1 (en) * 1998-12-18 2005-04-20 Scios Inc. Methods for detection and use of differentially expressed OSF-2 in diagnosis of cardiac hypertrophy
WO2001057062A1 (en) * 2000-02-03 2001-08-09 Gene Logic, Inc. Modulation of osf-2 in inflammatory and renal diseases
WO2002020055A1 (fr) * 2000-09-08 2002-03-14 Daiichi Suntory Pharma Co., Ltd. Médicaments contre les défaillances cardiaques
AU2002323120A1 (en) * 2001-08-13 2003-03-03 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
CN100348277C (zh) * 2005-08-09 2007-11-14 中国人民解放军第三军医大学 成骨细胞特异性转录因子－2基因修饰的组织工程化骨的构建方法
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
KR101363695B1 (ko) 2005-12-28 2014-02-14 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항페리오스틴에 대한 항체, 및 페리오스틴이 관여하는 질환의 예방 또는 치료를 위해 그것을 함유하는 약제학적 조성물
JP5238942B2 (ja) 2007-06-27 2013-07-17 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
EP2631302A3 (en) * 2008-03-31 2014-01-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US8420310B2 (en) * 2008-06-05 2013-04-16 Saga University Method for detection of idiopathic interstitial pneumonia
JP2012012344A (ja) * 2010-07-01 2012-01-19 Japan Health Science Foundation 創傷治癒剤
CA2817380C (en) 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
JP6183809B2 (ja) 2011-09-06 2017-08-23 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
WO2014136910A1 (ja) 2013-03-08 2014-09-12 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98109A (pt) * 1990-06-29 1992-07-31 Hoechst Japan Processo recombinante para a preparacao duma nova proteina
JPH09200324A (ja) * 1996-01-12 1997-07-31 Ricoh Co Ltd ファクシミリ装置

Also Published As

Publication number Publication date
EP0562508A3 (en) 1994-06-22
ATE167232T1 (de) 1998-06-15
DE69319012D1 (de) 1998-07-16
JPH05268982A (ja) 1993-10-19
CA2092768A1 (en) 1993-09-28
US5756664A (en) 1998-05-26
DK0562508T3 (da) 1999-03-29
GR3027671T3 (en) 1998-11-30
EP0562508B1 (en) 1998-06-10
EP0562508A2 (en) 1993-09-29
DE69319012T2 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
DE3884529D1 (de) Leader-anteile zur produktion von rekombinanten proteinen.
DE3772121D1 (de) Abtastendoskop zur chirurgischen verwendung.
DE59002803D1 (de) Verfahren zur Herstellung von natürlichem Vanillin.
DK0457430T3 (da) Kollagenkonstruktioner
DE3856433D1 (de) Triazolin(thi)on Zwischenprodukte zur Herstellung von Herbiziden
US5043429B1 (en) Protein fragments containing factor VIII binding domain of von willebrand factor
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE69308664D1 (de) Verfahren zur Herstellung von Silikonemulsionen
DE3853836D1 (de) Kontinuierliches Verfahren zur Herstellung von Äthylen-Propylen-Copolymeren.
DE69502384D1 (de) Prozess zur herstellung von polyarylenetherketonen
DE69118428D1 (de) Prozess zur Herstellung von Polyarylensulfiden
DE59300418D1 (de) Verfahren zur Herstellung von natürlichen Antioxidantien.
DE69008617D1 (de) Verfahren zur Herstellung von hydrophobem Material.
DE68923912D1 (de) Verfahren zur Herstellung von 3-Pyrrolidinol.
ATE107935T1 (de) Verfahren zur herstellung von propylen-ethylen- copolymerisaten.
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE3886367D1 (de) Verwendung von Antigestagenen zur Herstellung von Arzneimitteln.
DE69707910D1 (de) Prozess zur Herstellung von Dimethylpropylamin
DE69018050D1 (de) Verfahren zur Stabilisierung von Percarbonsäuren.
DE3888216D1 (de) Methode zur Herstellung von aminokohlenwasserstoff-substituierten Ketoximosilanen.
DE69007028D1 (de) Verfahren zur Herstellung von 3,4-Epoxybutyrat und Zwischenprodukte dafür.
DE69419312D1 (de) Verfahren zur Herstellung von weissem Kohlenstoff

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 562508

Country of ref document: ES